New Drugs in Hematology
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (30 October 2016) | Viewed by 31939
Special Issue Editor
Interests: strategies for hematopoietic stem cell transplantation in chronic lymphoproliferative disorders; toxicity of hematopoietic stem cell transplantation; population outcomes of hematologic malignancies
Special Issue Information
Dear Colleagues,
During the last two decades we have witnessed a complete transformation in how we approach blood cancers. A deeper understanding of the biology of specific hematologic malignancies has exposed numerous new therapeutic targets that were quickly followed by a plethora of novel therapeutic agents. The availability of novel drugs not only continues to improve patient outcomes but also generate numerous clinical questions. How to best combine or sequence new therapeutic agents? How to balance toxicity with the need for prolonged therapy? How cancer cells escape pharmacological suppression of a presumed vital pathway? How to make therapeutic innovations affordable to most patients? How to ensure barriers for clinical trial participation are removed so patients have early access to disease modifying agents while answering the relevant clinic questions? In this Special Issue of Pharmaceuticals experts discuss recent innovations in their fields and lay out the remaining key questions for the near future.
Dr. Luciano J. Costa
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- stem cell transplantation
- non-Hodgkin lymphoma
- Hodgkin lymphoma
- population outcomes
- clinical trials
- hematopoietic cells mobilization
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
